Luminex Corp. (NASDAQ:LMNX) shares saw an uptick in trading volume on Thursday . 211,991 shares were traded during trading, a decline of 4% from the previous session’s volume of 220,319 shares.The stock last traded at $21.08 and had previously closed at $20.92.

A number of research firms recently issued reports on LMNX. Piper Jaffray Cos. restated a “hold” rating and set a $20.00 target price (up from $19.00) on shares of Luminex Corp. in a research report on Tuesday, May 3rd. Leerink Swann reaffirmed a “hold” rating and issued a $22.00 price objective on shares of Luminex Corp. in a report on Tuesday, May 3rd. Finally, Zacks Investment Research cut shares of Luminex Corp. from a “buy” rating to a “hold” rating in a report on Thursday, April 28th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. Luminex Corp. presently has a consensus rating of “Hold” and an average price target of $20.83.

The company has a market capitalization of $938.74 million and a price-to-earnings ratio of 24.34. The company has a 50 day moving average price of $20.26 and a 200-day moving average price of $19.71.

Luminex Corp. (NASDAQ:LMNX) last issued its quarterly earnings results on Monday, May 2nd. The company reported $0.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.15. The business had revenue of $63 million for the quarter, compared to analyst estimates of $60.98 million. During the same quarter in the prior year, the company earned $0.23 EPS. The firm’s revenue for the quarter was up 9.2% on a year-over-year basis. Equities analysts forecast that Luminex Corp. will post $0.67 EPS for the current fiscal year.

A number of hedge funds have modified their holdings of LMNX. EQIS Capital Management boosted its stake in shares of Luminex Corp. by 883.5% in the fourth quarter. EQIS Capital Management now owns 46,942 shares of the company’s stock worth $1,004,000 after buying an additional 42,169 shares in the last quarter. Rhumbline Advisers boosted its stake in Luminex Corp. by 4.6% in the fourth quarter. Rhumbline Advisers now owns 69,917 shares of the company’s stock valued at $1,496,000 after buying an additional 3,100 shares during the period. California State Teachers Retirement System boosted its stake in Luminex Corp. by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 79,760 shares of the company’s stock valued at $1,706,000 after buying an additional 1,282 shares during the period. Oxford Asset Management boosted its stake in Luminex Corp. by 25.3% in the fourth quarter. Oxford Asset Management now owns 92,041 shares of the company’s stock valued at $1,984,000 after buying an additional 18,562 shares during the period. Finally, Nationwide Fund Advisors boosted its stake in Luminex Corp. by 259.4% in the fourth quarter. Nationwide Fund Advisors now owns 105,495 shares of the company’s stock valued at $2,257,000 after buying an additional 76,140 shares during the period.

Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company has a range of instruments using its xMAP technology, including its LUMINEX 100/200 systems offer 100-plex testing; the Company’s FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.